For Immediate Release
Dr. Robert Weiss to offer LaViv by FibrocellToday, the Maryland Dermatology Laser Skin and Vein Institute became one of only a handful of practices nationwide to offer the revolutionary new Fibrocell Science LaViv procedure. The LaViv procedure, approved today by the FDA, is the only one of its kind to use the patient’s own cells to regrow healthy collagen in the skin. It promises to be a revolutionary new alternative or adjunct treatment to conventional fillers, such as Restylane, Perlane, Radiesse, Juvederm, and Sculptra.
LaViv is a patented procedure whereby samples of a patient’s skin cells are taken, purified, and multiplied in order to create millions of fibroblast cells. These fibroblast cells are then injected back into the patient’s skin in order to smooth wrinkles, frown lines, and nose-to-mouth lines, and to regrow collagen to reduce the appearance of acne scarring. Fibroblast cells which occur naturally in skin are responsible for producing collagen, elastin, and hyaluronic acid, which give skin its soft, young look. Because the cells originate from the patient rather than a foreign source, the chance of an allergic reaction is extremely small, and results in patients have been shown to last for as many as seven years, without the recurring return treatments required by conventional fillers.
“The concept of using a patient’s own collagen-making cells is a revolutionary way to help treat nasolabial fold wrinkles and help restore a fresh appearance,” said Dr. Robert A. Weiss, Clinical Associate Professor, Johns Hopkins School of Medicine and Director, Maryland Laser Skin & Vein Institute, and an investigator for the laVív clinical trials. “Since this is a biological process that works over time, LaVív is able to provide gradual and natural-looking results.”
The Maryland Dermatology Laser, Skin and Vein Institute is a cosmetically oriented dermatology practice, originated by Drs. Robert & Margaret Weiss over 20 years ago, based in Hunt Valley (Baltimore), MD. The MDLSV Institute not only treats thousands of patients per year, but is a leading clinical research facility investigating new skin treatments and devices for the purposes of FDA clearance and improving patient treatments and outcomes. For additional information, please visit www.mdlsv.com or www.smoothskin.net
About laVív® (azficel-T)
Each person’s laVív treatment is unique because it is made from their own cells. Small fibroblast samples are taken from behind the patient’s ear and sent to the Fibrocell Science lab. Over a period of approximately 90 days, hundreds of millions of fibroblasts are cultured and then frozen until needed for treatment. The recommended course of laVív administration is a series of three treatments, typically three to six weeks apart. Additional information about laVív, including complete Prescribing Information, will be available on www.mylaviv.com within the coming days.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (OTCBB:FCSC.OB) is a cell therapy company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.